PFIZER stock news on Anadi Algo News

Monday, June 15, 2026
DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|DISCLAIMER: AI-generated signals are for informational purposes only. All trading and investment decisions are solely the user's responsibility.|Past performance does not guarantee future results. Trade at your own risk.|Anadi Algo is not a SEBI-registered advisor. Consult a qualified financial advisor before acting on any recommendation.|
Stock Landing|5 matching stories

PFIZER Share Price, Latest News & Sentiment

Latest AI-analyzed news for PFIZER, along with saved share-price context, sentiment, quarterly filing summary, and related names in one page.

Stock Coverage Hub

PFIZER News Today

Emerging stock coverage

Brand protection is vital in the competitive Indian pharmaceutical market.

Coverage
5
recent stories
Sources
2
distinct publishers
Bias Split
5 bullish / 0 bearish
0 neutral stories
Window
59d
recent coverage span
Saved Quote Snapshot

PFIZER

Last Updated
23 May 2026
Price
NA
NA
52W Range
NA - NA
exchange snapshot
PE / VWAP
PE NA
VWAP NA
Trend Read
bearish
Bearish stack · EMA 5 < 9 < 21 < 50
Business Context
Industry: NA
Sector Trail: NA
Listing Date: NA
Market Structure
F&O Eligible: No
Indices: NA
Snapshot Source: mcp+nse
Quarterly Read

Quarter ended 31 Dec 2024

Non-Consolidated results
What This Quarter Says

Pfizer's latest filing shows a revenue of Rs 537.99 crore and a profit of Rs 127.6 crore. This information is on record. These numbers tell us how much money the company made and how much profit was left after expenses.

Revenue
Rs 537.99 cr
down 8.6% vs previous filing
Profit
Rs 127.6 cr
down 19.4% vs previous filing
EPS / Finance Cost
EPS 27.89
Finance cost Rs 1.51 cr
Filing Context
Filed 31 Jan 2025, 11:07 pm
Figures are taken from the saved exchange filing, not from a live request.
Quick Reader Notes
  • Revenue this quarter: Rs 537.99 cr, down 8.6% vs previous filing.
  • Profit this quarter: Rs 127.6 cr, down 19.4% vs previous filing.
  • EPS gives a quick sense of per-share earnings: 27.89.
How To Read This

Treat this block as a saved quarter snapshot. First see whether revenue and profit are improving, then read the latest news below to judge whether recent headlines support that trend or work against it.

PFIZER FAQ

Why is PFIZER in the news right now?

PFIZER has appeared across 5 recent stories from 2 sources, which usually means there is a real flow of fresh headlines rather than a single isolated mention.

Is PFIZER coverage bullish or bearish right now?

PFIZER coverage is currently leaning bullish, with 5 bullish, 0 bearish, and 0 neutral analyzed stories in the recent window.

Which themes are moving with PFIZER?

Recent PFIZER coverage is clustering around Pharmaceuticals and Healthcare. Related names showing up alongside PFIZER include DIVISLAB, DRREDDY, GSKCONS.

How should I use this PFIZER news page?

Use this page as a coverage hub for PFIZER: start with the latest headlines, then check the dominant themes, related names, and saved market context before you form a trade or watchlist view.

Workflow View

Use PFIZER coverage to build a cleaner watchlist.

A stock page is most useful when it helps you slow down, compare headlines, and separate one-off noise from a repeatable setup.

This is here if you want to go deeper, not as a push.Explore Anadi
Positive for GSKCONS, reinforcing brand strength and market position.|Quick check: GSKCONS neutral, PFIZER neutral (-0.6% 1d).
et_marketsabout 1 month ago

US market today: Pfizer posts strong first-quarter, sees boost from recent legal wins

The Indian pharma sector is influenced by global regulatory signals and product pipelines. Positive news from a major global player like Pfizer can uplift overall sector sentiment, especially for export-oriented Indian companies.

Bullish+17.680%
5 facts
Maintain a neutral to slightly positive bias on Indian pharma stocks, focusing on companies with strong R&D and global market presence, but be mindful of the indirect nature of this news.|Quick check: SUNPHARMA bullish bias (overbought), CIPLA bullish bias (overbought).

Latest PFIZER Stock Coverage

While the article is old, the underlying theme of India's potential in pharma remains; consider long-term accumulation in quality Indian pharma and CRO stocks on dips.